New combo therapy may reduce need for long-term hormone drugs in prostate cancer
NCT ID NCT05162573
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This early-phase study tested a new approach for men with prostate cancer that has spread to nearby lymph nodes. The standard treatment includes radiation plus 2-3 years of hormone therapy, which can cause lasting side effects. Researchers added a targeted radioactive drug (Lu-PSMA) to the radiation, hoping to better control the cancer and possibly shorten or avoid hormone therapy. The study involved 14 participants and focused on finding the safest dose of the added drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Netherlands Cancer Institute
Amsterdam, 1066 CX, Netherlands
-
UMC Utrecht
Utrecht, 3508 GA, Netherlands
Conditions
Explore the condition pages connected to this study.